Background: The parenteral administration of antivenoms is the mainstay in snakebite envenoming therapy. The standardized protocol does not exist, but it is agreed that the intravenous (i.v.) route is more effective than the others, especially the intramuscular (i.m.) route, based on the monitoring of venom/antivenom pharmacokinetics in the systemic circulation. Recent evidence suggests that the lymphatic system may be crucial in abolishing venom action. Methods: A preclinical study was performed to determine the optimal administration route with emphasis on venom/antivenom interplay in both the blood and lymph of experimentally envenomed sheep. Timed level measurements were used to compare the antivenom effect on the decrement of venom quantities in both relevant body compartments. Hematological and coagulation parameters, as well as proportions of developed anti-antivenom IgGs, were evaluated. Results: The i.m. antivenom resulted in faster and greater lymphatic absorption and complete neutralization of the venom, whereas the i.v. antivenom only slowed its absorption. The total amount of venom reaching the lymph (AUC(0-t)) was two times lower after i.m. administration. In the systemic circulation, i.m. antivenom had a lower peak concentration (c(max)) and a longer time to reach it (t(max)). However, the total venom exposure was three times lower than with i.v. antivenom. Irrespective of the treatment approach, both groups showed improvement in blood disorders with no significant difference in humoral response against equine F(ab')(2) fragments. Conclusions:I.m. administration proved to be a viable option for the snakebite management.
Pharmacokinetics of Snake Antivenom Following Intravenous and Intramuscular Administration in Envenomed Large Animal Model.
在中毒大型动物模型中,静脉注射和肌肉注射蛇毒抗蛇毒血清后的药代动力学研究
阅读:4
作者:Gamulin Erika, Mateljak LukaÄeviÄ Sanja, Lang Balija Maja, SmajloviÄ Ana, Vnuk Dražen, Gulan Harcet Jadranka, TomiÄiÄ Maja, HeÄimoviÄ Ana, Halassy Beata, KurtoviÄ Tihana
| 期刊: | Pharmaceutics | 影响因子: | 5.500 |
| 时间: | 2025 | 起止号: | 2025 Feb 7; 17(2):212 |
| doi: | 10.3390/pharmaceutics17020212 | 研究方向: | 其它 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
